NCT06164275View on ClinicalTrials.gov

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2031

Conditions
Classic Hodgkin Lymphoma
Interventions
PROCEDURE

Biopsy

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Dacarbazine

Given IV

DRUG

Doxorubicin

Given IV

PROCEDURE

Echocardiography

Undergo echocardiography

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

DRUG

Vinblastine

Given IV

Trial Locations (4)

60134

Northwestern Delnor IL258, Geneva

60555

Cadence Health - CDH, Warrenville

60611

Northwestern University, Chicago

94305-5824

Stanford Cancer Center, Stanford

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT06164275 - Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter